ArticleERJ open research2025
Bronchial rheoplasty for chronic bronchitis: real-world evidence of safety and performance.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Identification of imaging-based pulmonary and extrapulmonary treatable traits in COPD: a review.Frontiers in medicine · 2026Review
- Uniform and Complete Irreversible Electroporation on Gastric Mucosa Enabled by Sintered Silver Hydrogel.Cyborg and bionic systems (Washington, D.C.) · 2026Article
- First report of bilateral Bronchial Rheoplasty for treating chronic bronchitis performed in a single procedure.European clinical respiratory journal · 2025Article
- Advancing towards personalized medicine: Practical specifications for management of treatable traits in patients with COPD exacerbations.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bronchial rheoplasty (BR) addresses mucosal inflammation and hypersecretion associated with chronic bronchitis (CB) by ablating goblet cell hyperplasia with nonthermal pulsed electric fields. This study assessed if BR continues to demonstrate a safe profile and symptom burden reduction in CB patients. Methods: This observational, post-market, single-arm registry was conducted at eight centres in Austria and Germany. Patients with CB and high symptom burden (COPD assessment test (CAT) score ≥7 points in the first two questions) were treated with two bronchoscopic BR procedures. The primary outcomes were safety and symptom burden at 12 months, evaluated by (serious) adverse events ((S)AEs) and questionnaire scores (CAT and St. George's Respiratory Questionnaire (SGRQ)). Subgroup analyses were performed to identify treatment responders. Results: 106 BR procedures were performed in 54 patients (mean forced expiratory volume in 1 s (FEV Conclusion: The real-world clinical experience demonstrates that BR is a relatively safe and promising treatment option for CB patients with significant symptom burden.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.